What are the treatment options for metastatic squamous cell carcinoma of the lung?

Treatment Options for Metastatic Squamous Cell Carcinoma of the Lung

For patients with metastatic squamous cell carcinoma of the lung and good performance status (PS 0-1), pembrolizumab combined with carboplatin and paclitaxel (or nab-paclitaxel) should be considered the standard first-line treatment in the absence of contraindications to immunotherapy. 1

First-Line Treatment Algorithm

For Patients with PS 0-1 (Good Performance Status)

Preferred Regimen:

• Pembrolizumab + carboplatin + paclitaxel or nab-paclitaxel is the standard choice with 100% consensus agreement in Pan-Asian guidelines 1
• This combination demonstrates survival benefit across all PD-L1 expression levels 2
• Recent network meta-analysis confirms paclitaxel-based doublet chemotherapy combined with PD-(L)1 checkpoint inhibitors ranks highest for PFS (SUCRA: 96.52%) and among top three for OS (SUCRA: 83.58%) 3

Alternative Immunotherapy-Based Options:

• Atezolizumab + carboplatin + nab-paclitaxel represents another option (83% complete agreement, 17% with reservation) 1
• Nivolumab + ipilimumab for patients with high tumor mutational burden (TMB), regardless of PD-L1 expression 1

If Contraindications to Immunotherapy Exist:

• Platinum-based doublet chemotherapy with third-generation cytotoxic agents (gemcitabine, vinorelbine, or taxanes) 1
• Administer 4 cycles followed by maintenance monotherapy, or up to maximum 6 cycles if maintenance unsuitable 1

Special Consideration:

• Necitumumab + gemcitabine + cisplatin may be considered for squamous cell carcinoma expressing EGFR by immunohistochemistry (83% agreement) 1

For Patients with PS 2 (Moderate Performance Status)

• Carboplatin-based combination therapy should be considered in eligible PS 2 patients 1
• Single-agent chemotherapy (gemcitabine, vinorelbine, or docetaxel) represents an alternative 1
• Chemotherapy prolongs survival and improves quality of life compared to best supportive care alone 1

For Patients with PS 3-4 (Poor Performance Status)

• Best supportive care only 1
• Exception: if molecularly targetable alteration identified where treatment has minimal toxicity 1

Maintenance Therapy

After completing first-line platinum-based chemotherapy (for PS 0-1 patients):

• Continuation maintenance with gemcitabine is an option if treated with cisplatin-gemcitabine 1
• Decisions should consider histology, response to platinum-doublet, remaining toxicity, PS, and patient preference 1

Second-Line Treatment Considerations

Following progression on first-line immunotherapy-chemotherapy combinations, effective second-line options are limited 4, 5:

• Docetaxel with or without ramucirumab 6, 5
• Afatinib (oral administration advantage) 6, 5
• Pemetrexed if not given in first line 6
• Nintedanib-docetaxel 6

Critical Caveats

Molecular Testing:

• While actionable mutations are rare in squamous cell carcinoma (2-10% cumulative incidence), molecular testing should still be considered, particularly in never-smokers and mixed histology 7
• Testing for EGFR, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, and ERBB2 should be considered 7

PD-L1 Testing:

• Upfront PD-L1 expression testing is category 1 recommendation before first-line therapy 7
• However, for squamous cell carcinoma, immunotherapy combinations are recommended regardless of PD-L1 status in PS 0-1 patients 1

Smoking Cessation:

• Should be highly encouraged at any stage as it improves outcomes 1

Treatment Toxicity:

• Grade ≥3 toxicity occurs in approximately 33% with nivolumab + ipilimumab 2
• Serious adverse events occur in 57% with nivolumab + ipilimumab + chemotherapy combinations 2
• Consider patient's ability to tolerate treatment when selecting regimen

The most recent 2023 ESMO guidelines 6 and 2024 NCCN/ASCO guidelines 2, 7 strongly support immunotherapy-chemotherapy combinations as the standard of care for metastatic squamous cell carcinoma, representing a paradigm shift from historical chemotherapy-only approaches.